Akari Short Term Debt vs Net Debt Analysis

AKTX Stock

USD 1.30 0.06 4.84%

Akari Therapeutics financial indicator trend analysis is way more than just evaluating Akari Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akari Therapeutics PLC is a good investment. Please check the relationship between Akari Therapeutics Short Term Debt and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Short Term Debt vs Net Debt

Short Term Debt vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akari Therapeutics PLC Short Term Debt account and Net Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Akari Therapeutics' Short Term Debt and Net Debt is 0.42. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Net Debt in the same time period over historical financial statements of Akari Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Akari Therapeutics' Short Term Debt and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Akari Therapeutics PLC are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Short Term Debt i.e., Akari Therapeutics' Short Term Debt and Net Debt go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Short Term Debt

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Akari Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to drop to about (3 M) in 2024

	2021	2022	2023	2024 (projected)
Net Interest Income	10.6K	45.9K	41.3K	70.5K
Interest Income	10.6K	45.9K	41.3K	39.3K

Net Interest Income Interest Income

Akari Therapeutics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Current Assets Total	Property Plant And Equipment Gross	Short Term Debt	Current Deferred Revenue	Short Long Term Debt	Intangible Assets	Other Liab	Net Tangible Assets
Common Stock Shares Outstanding		0.73	0.66	0.66	0.73	-0.71	-0.16	0.42	0.71	0.73	0.83	0.63	-0.35	0.2	0.64	0.73	0.64	-0.45	0.93	0.01	-0.45	-0.55	-0.54	0.79	0.27	0.6
Total Assets	0.73		0.85	0.88	0.99	-0.99	0.06	0.74	0.99	1.0	0.4	0.59	-0.23	0.14	0.88	1.0	0.58	-0.43	0.86	-0.12	-0.43	-0.49	-0.47	0.87	0.05	0.93
Other Current Liab	0.66	0.85		0.99	0.77	-0.86	-0.26	0.57	0.86	0.85	0.33	0.48	-0.22	0.36	0.99	0.85	0.49	-0.44	0.68	0.12	-0.44	-0.56	-0.53	0.79	0.1	0.79
Total Current Liabilities	0.66	0.88	0.99		0.81	-0.89	-0.23	0.69	0.89	0.88	0.31	0.47	-0.17	0.35	1.0	0.88	0.47	-0.4	0.69	0.12	-0.4	-0.55	-0.52	0.82	0.1	0.83
Total Stockholder Equity	0.73	0.99	0.77	0.81		-0.97	0.12	0.73	0.97	0.99	0.42	0.58	-0.23	0.07	0.81	0.99	0.58	-0.44	0.88	-0.15	-0.44	-0.46	-0.44	0.85	0.07	0.92
Net Debt	-0.71	-0.99	-0.86	-0.89	-0.97		-0.07	-0.74	-1.0	-0.99	-0.33	-0.55	0.25	-0.12	-0.89	-0.99	-0.55	0.42	-0.84	0.12	0.42	0.46	0.44	-0.84	0.01	-0.91
Retained Earnings	-0.16	0.06	-0.26	-0.23	0.12	-0.07		-0.08	0.07	0.08	-0.29	0.03	-0.53	-0.92	-0.21	0.06	0.01	0.58	0.11	-0.87	0.58	0.66	0.68	-0.28	-0.27	0.11
Accounts Payable	0.42	0.74	0.57	0.69	0.73	-0.74	-0.08		0.74	0.72	0.12	0.24	0.13	0.22	0.68	0.74	0.24	-0.2	0.51	0.13	-0.2	-0.38	-0.36	0.69	0.07	0.76
Cash	0.71	0.99	0.86	0.89	0.97	-1.0	0.07	0.74		0.99	0.33	0.55	-0.25	0.11	0.89	0.99	0.55	-0.41	0.84	-0.12	-0.41	-0.46	-0.44	0.84	-0.02	0.91
Cash And Short Term Investments	0.73	1.0	0.85	0.88	0.99	-0.99	0.08	0.72	0.99		0.38	0.56	-0.27	0.1	0.88	1.0	0.56	-0.41	0.86	-0.13	-0.41	-0.46	-0.44	0.84	0.06	0.93
Net Receivables	0.83	0.4	0.33	0.31	0.42	-0.33	-0.29	0.12	0.33	0.38		0.66	-0.13	0.33	0.3	0.4	0.66	-0.45	0.71	0.04	-0.45	-0.55	-0.54	0.66	0.18	0.21
Common Stock Total Equity	0.63	0.59	0.48	0.47	0.58	-0.55	0.03	0.24	0.55	0.56	0.66		-0.36	0.04	0.49	0.59	1.0	-0.35	0.73	-0.42	-0.35	-0.44	-0.42	0.76	-0.11	0.36
Non Current Liabilities Total	-0.35	-0.23	-0.22	-0.17	-0.23	0.25	-0.53	0.13	-0.25	-0.27	-0.13	-0.36		0.63	-0.19	-0.23	-0.36	-0.23	-0.42	0.6	-0.23	-0.23	-0.23	-0.02	-0.17	-0.23
Other Stockholder Equity	0.2	0.14	0.36	0.35	0.07	-0.12	-0.92	0.22	0.11	0.1	0.33	0.04	0.63		0.33	0.14	0.05	-0.64	0.01	0.79	-0.64	-0.73	-0.75	0.44	0.04	0.05
Total Liab	0.64	0.88	0.99	1.0	0.81	-0.89	-0.21	0.68	0.89	0.88	0.3	0.49	-0.19	0.33		0.88	0.5	-0.4	0.69	0.09	-0.4	-0.53	-0.5	0.82	0.09	0.83
Total Current Assets	0.73	1.0	0.85	0.88	0.99	-0.99	0.06	0.74	0.99	1.0	0.4	0.59	-0.23	0.14	0.88		0.58	-0.43	0.86	-0.11	-0.43	-0.49	-0.47	0.87	0.05	0.93
Common Stock	0.64	0.58	0.49	0.47	0.58	-0.55	0.01	0.24	0.55	0.56	0.66	1.0	-0.36	0.05	0.5	0.58		-0.36	0.73	-0.4	-0.36	-0.45	-0.43	0.76	-0.09	0.37
Short Long Term Debt Total	-0.45	-0.43	-0.44	-0.4	-0.44	0.42	0.58	-0.2	-0.41	-0.41	-0.45	-0.35	-0.23	-0.64	-0.4	-0.43	-0.36		-0.37	-0.52	1.0	0.83	0.82	-0.57	-0.16	-0.27
Non Current Assets Total	0.93	0.86	0.68	0.69	0.88	-0.84	0.11	0.51	0.84	0.86	0.71	0.73	-0.42	0.01	0.69	0.86	0.73	-0.37		-0.26	-0.37	-0.48	-0.46	0.83	0.06	0.72
Property Plant And Equipment Gross	0.01	-0.12	0.12	0.12	-0.15	0.12	-0.87	0.13	-0.12	-0.13	0.04	-0.42	0.6	0.79	0.09	-0.11	-0.4	-0.52	-0.26		-0.52	-0.49	-0.51	0.05	0.39	-0.04
Short Term Debt	-0.45	-0.43	-0.44	-0.4	-0.44	0.42	0.58	-0.2	-0.41	-0.41	-0.45	-0.35	-0.23	-0.64	-0.4	-0.43	-0.36	1.0	-0.37	-0.52		0.83	0.82	-0.57	-0.16	-0.27
Current Deferred Revenue	-0.55	-0.49	-0.56	-0.55	-0.46	0.46	0.66	-0.38	-0.46	-0.46	-0.55	-0.44	-0.23	-0.73	-0.53	-0.49	-0.45	0.83	-0.48	-0.49	0.83		0.99	-0.71	-0.13	-0.34
Short Long Term Debt	-0.54	-0.47	-0.53	-0.52	-0.44	0.44	0.68	-0.36	-0.44	-0.44	-0.54	-0.42	-0.23	-0.75	-0.5	-0.47	-0.43	0.82	-0.46	-0.51	0.82	0.99		-0.69	-0.17	-0.33
Intangible Assets	0.79	0.87	0.79	0.82	0.85	-0.84	-0.28	0.69	0.84	0.84	0.66	0.76	-0.02	0.44	0.82	0.87	0.76	-0.57	0.83	0.05	-0.57	-0.71	-0.69		0.01	0.71
Other Liab	0.27	0.05	0.1	0.1	0.07	0.01	-0.27	0.07	-0.02	0.06	0.18	-0.11	-0.17	0.04	0.09	0.05	-0.09	-0.16	0.06	0.39	-0.16	-0.13	-0.17	0.01		0.24
Net Tangible Assets	0.6	0.93	0.79	0.83	0.92	-0.91	0.11	0.76	0.91	0.93	0.21	0.36	-0.23	0.05	0.83	0.93	0.37	-0.27	0.72	-0.04	-0.27	-0.34	-0.33	0.71	0.24

Click cells to compare fundamentals

Akari Therapeutics Account Relationship Matchups

Akari Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	915.5K	1.6M	2.1M	3.1M	4.9M	4.7M
Total Assets	10.3M	17.6M	11.6M	13.8M	4.4M	4.1M
Other Current Liab	4.2M	1.8M	4.3M	11.1M	2.9M	5.7M
Total Current Liabilities	5.5M	5.2M	6.1M	12.0M	4.6M	7.9M
Total Stockholder Equity	3.8M	12.4M	5.6M	1.8M	(229K)	(217.6K)
Net Debt	(5.7M)	(14.1M)	(9.4M)	(13.2M)	(3.8M)	(4.0M)
Retained Earnings	(138.2M)	(156.6M)	(199.7M)	(217.5M)	(227.5M)	(216.1M)
Accounts Payable	1.2M	3.4M	1.8M	947K	1.7M	2.1M
Cash	5.7M	14.1M	9.4M	13.2M	3.8M	3.7M
Cash And Short Term Investments	5.7M	14.1M	9.4M	13.2M	3.8M	3.7M
Common Stock Total Equity	22.9M	23.7M	32.0M	384.7K	442.4K	420.3K
Liabilities And Stockholders Equity	10.3M	17.6M	11.6M	13.8M	4.4M	4.1M
Non Current Liabilities Total	1.0M	3.4M	4.3M	946.7K	1.1M	1.1M
Other Stockholder Equity	122.3M	191.9M	205.3M	219.3M	174.8M	117.1M
Total Liab	6.5M	5.2M	6.1M	12.0M	4.6M	8.1M
Total Current Assets	10.3M	17.6M	11.6M	13.8M	4.3M	4.1M
Accumulated Other Comprehensive Income	(12.2M)	(10.9M)	(541.0K)	(770.8K)	51.2M	53.7M
Common Stock	32.0M	385K	476.0K	744.5K	1.3M	1.3M
Non Current Assets Total	35K	27K	22.9K	16.9K	14K	13.3K
Property Plant And Equipment Gross	20.4K	5.0K	172K	164.9K	197.8K	207.7K
Intangible Assets	30K	27K	22.9K	16.9K	14K	13.3K
Net Tangible Assets	3.1M	(1.8M)	9.4M	5.5M	5.0M	4.7M
Non Currrent Assets Other	142.2K	585K	0.0	14.0K	16.1K	15.3K
Other Current Assets	1.0M	521.9K	2.3M	564.8K	496K	954.4K
Net Invested Capital	(1.8M)	9.4M	5.6M	1.8M	1.6M	1.5M
Net Working Capital	(1.8M)	9.4M	5.5M	1.8M	1.6M	1.5M
Capital Stock	32.0M	384.7K	476.0K	744.5K	670.0K	636.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akari Short Term Debt vs Net Debt Analysis

Short Term Debt vs Net Debt

Short Term Debt vs Net Debt Correlation Analysis

Correlation Coefficient

Short Term Debt

Net Debt

Akari Therapeutics fundamental ratios Correlations

Akari Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akari Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Akari Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Short Term Debt	+ 1.0	Short Long Term Debt Total

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Net Debt	- 0.97	Total Stockholder Equity
Other Stockholder Equity	- 0.92	Retained Earnings